Desirudin - Biologic Drug Details

Summary for desirudin

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for desirudin Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for desirudin Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Bausch Health Us, Llc	IPRIVASK	desirudin	For Injection	021271		2006-11-13	DrugPatentWatch analysis and company disclosures
Bausch Health Us, Llc	IPRIVASK	desirudin	For Injection	021271		2008-01-19	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for desirudin Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Bausch Health Us, Llc	IPRIVASK	desirudin	For Injection	021271		2036-12-20	Patent claims search
Bausch Health Us, Llc	IPRIVASK	desirudin	For Injection	021271		2035-11-05	Patent claims search
Bausch Health Us, Llc	IPRIVASK	desirudin	For Injection	021271		2035-01-21	Patent claims search
Bausch Health Us, Llc	IPRIVASK	desirudin	For Injection	021271		2031-10-13	Patent claims search
Bausch Health Us, Llc	IPRIVASK	desirudin	For Injection	021271		2037-08-25	Patent claims search
Bausch Health Us, Llc	IPRIVASK	desirudin	For Injection	021271		2037-07-17	Patent claims search
Bausch Health Us, Llc	IPRIVASK	desirudin	For Injection	021271		2038-12-19	Patent claims search

Summary

Last updated: February 15, 2026

Desirudin, a recombinant hirudin derivative, is an anticoagulant approved primarily for deep vein thrombosis (DVT) prophylaxis. Its market relevance hinges on evolving therapeutic preferences, patent status, competition, and regulatory pathways. While marketed in some regions, its commercial trajectory faces challenges from newer anticoagulants. Investment decisions depend on ongoing clinical developments, patent expirations, and potential market expansion.

Market Dynamics

Therapeutic Use and Competitive Landscape

Desirudin's primary indication, DVT prevention in patients undergoing orthopedic surgery, faces competition from multiple direct oral anticoagulants (DOACs) such as rivaroxaban, apixaban, and dabigatran. These agents offer oral administration, reducing observational burdens because desirudin is administered via subcutaneous injection.

Market Penetration

• Market approval: Desirudin received FDA approval in 2003 for DVT prophylaxis (Lovenox, an alternate agent, was already established, and fondaparinux entered markets later).
• Prominent regions: United States, select European countries.
• Usage trends: Declining in favor of oral agents and agents with broader indications.

Regulatory Landscape

• US: Approved as a second-line prophylactic agent, with limited expansion.
• Europe: Approved for DVT prevention but less frequently used due to competition.
• Off-label Uses: Minimal, as clinical guidelines favor other agents.

Patent and Manufacturing

• Patent status: As of 2023, the original patent expired around 2017. No recent biologic exclusivity extensions are active.
• Biosimilar development: No biosimilars yet announced, but potential exists following patent expiration.

Financial Trajectory

Sales History

• Peak sales (early 2000s): Estimated $30 million annually in the US.
• Recent figures (2021-2022): Under $10 million, reflecting declining market share.

Revenue Drivers

• Market acceptance: Limited to specific surgical procedures.
• Reimbursement policies: Favor oral anticoagulants with simplified administration.
• Price point: Higher than oral options due to injection administration and biologic manufacturing costs.

Challenges and Opportunities

Challenges

• Competition from cheaper, convenient oral DOACs.
• Limited indication expansion prospects.
• Administrative and patient compliance hurdles with injectable drugs.
• Patent expiration reducing exclusivity and pricing ability.

Opportunities

• Development of new formulations or delivery methods.
• Expanding indications to other thrombotic conditions.
• Licensing or partnership agreements to leverage broader distribution channels.
• Clinical trials targeting markets like thrombosis in cancer or atrial fibrillation.

Strategic Outlook

Unless driven by novel delivery systems or expanded indications, desirudin's market presence is expected to decline further over the next five years. Growth prospects hinge on niche applications or re-purposing, supported by clinical research.

Key Market Data Summary

Attribute	Details
US peak sales	~$30 million (early 2000s)
2022 revenue	< $10 million
Patent expiry	2017 (original patent)
Approved indications	DVT prophylaxis post-orthopedic surgery
Competition	Rivaroxaban, apixaban, dabigatran (oral agents)
Biosimilar presence	Not yet launched

Key Takeaways

• Desire for injectable anticoagulants diminishes as oral DOACs capture market share.
• Patent expiry in 2017 opened development pathways for biosimilars, but none have launched.
• Future growth depends on expanding indications and innovative delivery options.
• Investment risks include market decline and entry of competing biosimilars.
• Clinical research and strategic partnerships could sustain relevance in niche markets.

FAQs

1. What factors mainly influence desirudin’s decline in market share?
   The advent of oral anticoagulants offering easier administration, broader indications, and lower costs reduces desirudin’s appeal.

2. Are biosimilars likely to impact desirudin’s market?
   Yes; patent expiry in 2017 opens potential for biosimilar development, which could further pressure pricing and sales.

3. Can desirudin be repositioned for new therapeutic areas?
   Possible but depends on clinical trial outcomes, regulatory approvals, and market demand for alternative thrombotic conditions.

4. What regulatory challenges could impede desirudin’s growth?
   Approval pathways for new indications or formulations may be complex, and existing competitors have established safety profiles.

5. What is the outlook for desirudin in the next five years?
   Market demand will likely decline unless new innovations or indications emerge, or strategic partnerships extend its relevance.

Citations

[1] U.S. Food and Drug Administration. Desirudin (Iprivask) approval history. 2003.
[2] IMS Health. Anticoagulant market reports, 2022.
[3] European Medicines Agency. Desirudin summary of product characteristics. 2019.